Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2012

View Archived Issues

Novel products patented at Merck & Co.

New agents for hypertension divulged

HIV integrase inhibitors discovered by U.S. and Canadian team

Shionogi & Co. patents novel beta-secretase inhibitors

Glaucoma gene therapy protects retinal ganglion cells

Vertex provides additional data from VX-809/Kalydeco combination study

Marshall Edwards updates on phase I study of anticancer candidate

Modification of EarlyCDT-Lung significantly increases specificity and overall accuracy of the test

New cancer/testis antigen may be biomarker for renal cell carcinoma

Soricimed Biopharma clear to commence phase I trial of novel anticancer agent

Boehringer Ingelheim discloses novel FLAP inhibitors

Eurocine Vaccines reports on pneumococcal glycoconjugate vaccine

EMA committee issues opinion on orphan drug status for sickle cell disease therapy

Canadian study reveals novel blood biomarker for osteoarthritis

Research collaboration agreement set for stem cell and tissue repair research

First patients treated in corneal epithelial stem cell transplant study

Flexion's lead osteoarthritis product relieves pain in phase II trial

Preliminary phase III data show efficacy for CompleoTRT

Alnylam reports on phase IIb ALN-RSV01 trial

Celsion completes enrollment in pivotal HEAT study

City of Hope obtains grant to develop T-cell treatment targeting brain tumor cells

Chemokine CXCR4 receptor antagonist shows promise in resistant/refractory AML

FDA requires integrated safety analysis before continued studies of oral Proellex

Phase I RenaZorb study enrolls first patients

Omni Bio provides updated results from pilot study in type 1 diabetes

Alkermes announces development decision regarding ALKS-37

Actelion launches drug in Japan for Niemann-Pick type C disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...